Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:
|
|
04 April 2025
| Name: | STEM CELL SCIENCES PLC (STC) (This company subsequently changed its name and is now ASSET REALISATION COMPANY PLC. You should refer to that name for Status.) | ||||||
| Date of Listing: | 16 April 2007 | ||||||
| Subsequent Names: |
|
Stock Exchange Status:
This company subsequently changed its name and is now ASSET REALISATION COMPANY PLC. You should refer to that name for Stock Exchange Status.Legal Status:
This company subsequently changed its name and is now ASSET REALISATION COMPANY PLC. You should refer to that name for Legal Status.Capital Gains Tax (CGT) Status:
This company subsequently changed its name and is now ASSET REALISATION COMPANY PLC. You should refer to that name for Capital Gains Tax Status.
Updates, corrections, disagreements please email to admin@delisted.com.au
Further information: deListed and InvestoGain are operated by Investogain Pty Limited which is licensed by ASIC as an Australian Financial Services Licensee (AFSL 334036). deListed acquires only securities that it deems to be of little or no value, in circumstances where the holder is unable to sell their securities on-market in the normal manner. This service has been provided online via the company’s website www.delisted.com.au since 2004.
Getting advice: Information provided in this section is of a general nature and applicable only to Australian tax residents who hold their investments on capital account (ie for long-term investment purposes). It has been prepared without taking into account your financial needs or tax situation. Before acting on the information, deListed suggests that you consider whether it is appropriate for your circumstances and recommends that you seek independent legal, financial, or taxation advice.
Disclaimer: The information provided above is to the best of our knowledge accurate as of today. But you should bear in mind that it is of a general nature and does not constitute financial or tax advice. Investogain Pty Limited accepts no liability for any loss arising from reliance on this information, including reliance on information that is no longer current.
| Company | FROM | TO |
|---|---|---|
| ASSET REALISATION COMPANY PLC | 08/04/2009 | |
| STEM CELL SCIENCES PLC | 08/04/2009 |
REGISTRY:
Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail
name changed to Asset Realisation Company PLC | 08/04/2009 |
following completion of the sale of the trading subsidiaries of the Company and certain ancillary agreements, assets, properties and rights, the Company's name has now been changed to "Asset Realisation Company Plc". Please note that the Company's new website address is, www.assetrealco.com | 03/04/2009 |
company advises of the completion of the disposal of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights (the "Disposal"), in accordance with the terms of the Disposal Agreement ( "Completion") - pursuant to the terms of the Disposal Agreement, the Company received at Completion: (i) 2,120,000 StemCells, Inc. Shares; (ii) a waiver of circa $715,000 (being the amount owed by the Company in respect of the StemCells, Inc. Loans); and (iii) the contingent right to receive up to 530,000 further Stem Cells, Inc. Shares subject to the terms of the escrow arrangements | 02/04/2009 |
company announces that at the Company's Extraordinary General Meeting ("EGM") held on Friday, all resolutions were duly approved by shareholders, present in person or by proxy, by 99% of the votes cast representing 64% of the total issued share capital | 30/03/2009 |
company announces that it has entered into a definitive agreement with StemCells, Inc. a publicly traded Delaware corporation (Nasdaq: STEM), for the sale of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights for a maximum total consideration of approximately US$4,849,000 | 03/03/2009 |
provides Notice of an Extraordinary General Meeting of Stem Cell Sciences Plc, to be held at the offices of Daniel Stewart & Company Plc, 36 Old Jewry, London, EC2R 8DD, UK at 11.00 a.m. on 27 March 2009 | 03/03/2009 |
the company will not be filing its preliminary results for the year ended 31st December 2008 - this is due to the Company considering an offer on its operating subsidiaries (Stem Cell Sciences Holdings Limited, Stem Cell Sciences Australia (Pty) Limited and Stem Cell Sciences UK Limited) - Stem Cell Sciences intends to remain suspended until further notice | 26/02/2009 |
directors believe that, given the current investment climate, the Company will deliver better shareholder value by selling substantially all of its operating assets and liabilities - a further announcement on this is expected to be made shortly | 11/02/2009 |
announces the signing of a further licence to its IRES technology - the undisclosed licensee is a major research-based international pharmaceutical company in the top 20 by market capitalisation and annual sales and it will use the technology in its own research and development activities - financial terms are not disclosed for this fully paid-up licence, which was signed during the Christmas holiday period | 05/01/2009 |
company announces that it has received 200,000 by way of a secured loan for working capital purposes - in exchange the third party lender has been granted a period of exclusivity to conduct further due diligence in respect of the Company's business and assets | 29/12/2008 |
the Company is still in discussions with a number of third parties about various options, including possible refinancing, divestiture of certain operations and/or merger opportunities of the Company, which may include an offer for the Company. There can be no certainty that any of the above transactions will proceed or that an offer will be made for the Company or as to the terms on which any such offer might be made. As a result of this announcement the Company is now in an Offer Period under the rules of the United Kingdom Takeover Code | 09/12/2008 |
the securities of Stem Cell Sciences Plc (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 26/11/2008 |
suspension of trading in the securities of Stem Cell Sciences Plc (the "Company") will be lifted immediately, following receipt of the Company's Full Year Accounts for the period ended 31 December 2007 | 02/04/2008 |
shares suspended from quotation following failure to lodge full year accounts for the period ended 31 December 2007 | 01/04/2008 |
name changed to Asset Realisation Company PLC | 08/04/2009 |
following completion of the sale of the trading subsidiaries of the Company and certain ancillary agreements, assets, properties and rights, the Company's name has now been changed to "Asset Realisation Company Plc". Please note that the Company's new website address is, www.assetrealco.com | 03/04/2009 |
company advises of the completion of the disposal of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights (the "Disposal"), in accordance with the terms of the Disposal Agreement ( "Completion") - pursuant to the terms of the Disposal Agreement, the Company received at Completion: (i) 2,120,000 StemCells, Inc. Shares; (ii) a waiver of circa $715,000 (being the amount owed by the Company in respect of the StemCells, Inc. Loans); and (iii) the contingent right to receive up to 530,000 further Stem Cells, Inc. Shares subject to the terms of the escrow arrangements | 02/04/2009 |
company announces that at the Company's Extraordinary General Meeting ("EGM") held on Friday, all resolutions were duly approved by shareholders, present in person or by proxy, by 99% of the votes cast representing 64% of the total issued share capital | 30/03/2009 |
company announces that it has entered into a definitive agreement with StemCells, Inc. a publicly traded Delaware corporation (Nasdaq: STEM), for the sale of the Trading Subsidiaries of the Company and certain ancillary agreements, assets, properties and rights for a maximum total consideration of approximately US$4,849,000 | 03/03/2009 |
provides Notice of an Extraordinary General Meeting of Stem Cell Sciences Plc, to be held at the offices of Daniel Stewart & Company Plc, 36 Old Jewry, London, EC2R 8DD, UK at 11.00 a.m. on 27 March 2009 | 03/03/2009 |
the company will not be filing its preliminary results for the year ended 31st December 2008 - this is due to the Company considering an offer on its operating subsidiaries (Stem Cell Sciences Holdings Limited, Stem Cell Sciences Australia (Pty) Limited and Stem Cell Sciences UK Limited) - Stem Cell Sciences intends to remain suspended until further notice | 26/02/2009 |
directors believe that, given the current investment climate, the Company will deliver better shareholder value by selling substantially all of its operating assets and liabilities - a further announcement on this is expected to be made shortly | 11/02/2009 |
announces the signing of a further licence to its IRES technology - the undisclosed licensee is a major research-based international pharmaceutical company in the top 20 by market capitalisation and annual sales and it will use the technology in its own research and development activities - financial terms are not disclosed for this fully paid-up licence, which was signed during the Christmas holiday period | 05/01/2009 |
company announces that it has received 200,000 by way of a secured loan for working capital purposes - in exchange the third party lender has been granted a period of exclusivity to conduct further due diligence in respect of the Company's business and assets | 29/12/2008 |
the Company is still in discussions with a number of third parties about various options, including possible refinancing, divestiture of certain operations and/or merger opportunities of the Company, which may include an offer for the Company. There can be no certainty that any of the above transactions will proceed or that an offer will be made for the Company or as to the terms on which any such offer might be made. As a result of this announcement the Company is now in an Offer Period under the rules of the United Kingdom Takeover Code | 09/12/2008 |
the securities of Stem Cell Sciences Plc (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement by the Company | 26/11/2008 |
suspension of trading in the securities of Stem Cell Sciences Plc (the "Company") will be lifted immediately, following receipt of the Company's Full Year Accounts for the period ended 31 December 2007 | 02/04/2008 |
shares suspended from quotation following failure to lodge full year accounts for the period ended 31 December 2007 | 01/04/2008 |
Your browser may reflect a date of printing in American format.
| NAME | TITLE | DATE OF APPT |
|---|---|---|
| Alastair Riddell | Executive Director | 19/11/2007 |
| Sue Furber | Company Secretary | |
| David Newton | Company Secretary |
Date of first appointment, title may have changed.
Date of first appointment, title may have changed.
Contact Us | Financial Services Guide | Privacy Policy
This website is owned and operated by Investogain Pty Limited.
ABN 88 129 443 447 | AFSL 334036
Information provided is of a general nature and not for trading or advice.
Copyright © 2002-2025 Investogain Pty Limited. All rights reserved.
